2ND ANNUAL HEALING NET FOUNDATION SUMMIT PARTICIPANT BIOGRAPHIES

FEBRUARY 21-23, 2017 • THE CHARTER • BEAVER CREEK, CO

www.TheHealingNet.org
The Healing NET Foundation 2nd Annual Summit | February 21-23, 2017 | Beaver Creek, CO

Co-Hosts
Allen Cohn, MD
Eric Liu, MD
Charles Nutting, DO

Scientific Advisory Committee (SAC)
George Fisher, MD, PhD
David Metz, MD
Kjell Oberg, MD, PhD*
Tom O’Dorisio, MD

FACULTY
Lowell Anthony, MD, FACP
Joy Ardill, BSc, BD, PhD, FRCPath
Martin Auerbach, MD
Lisa Bodei, MD, PhD*
Phillip Boudreaux, MD
Arvind Dasari, MD
Ebrahaim Delpassand, MD
Joseph Dillon, MD
Enrique Esparza, BS
Joseph Fuselier, MBA
Dan Granberg, MD, PhD*
Daniel M. Halperin, MD
Anthony Heaney, MD, PhD
Randy Hecht, MD
Andrew Hendifar, MD, MPH
Ken Herrmann, MD, MBA
Tim Hobday, MD
Mark Kidd, MD, PhD
Michelle Kim, MD
Michael Morse, MD
Sue O’Dorisio, MD, PhD
Richard Parker, MD
Scott Paulson, MD
Philip Philip, MD, PhD, FRCP
Alexandria Phan, MD
Robert Ramirez, DO, FACP
Walid Shaib, MD
Michael Soulen, MD
Laura Tang, MD
Yi-Zarn Wang, DDS, MD, FACS
James Yao, MD
Dominic Yee, MD

*European Neuroendocrine Tumor Society (ENETS)
**NURSES**

Bonita (Bonnie) Bennett, RN, BSN

Laura Devor, MSN, RN, ANP-BC, AOCNP

Linda Gardner, BSN, RN, VA-BC Pamela Gaytan, RN, BSN

Angela Laffan, MS, NP

Lorrie McSherry, BSN, RN, OCN

Anita Piano, MSN, RN, VA-BC

Pamela Ryan, BSN, RN

Sarah Smith, BSN, RN

Dana Stafford, RN

Tiffany Valone, PA-C, MS, OT

Donna Williams, RN

**Patient Advocates**

Kari Brendtro

Ron Hollander

Giovanna Imbesi

Cindy Lovelace

Joshua Mailman

Mary Mitchell Zoeller
Martin Allen-Auerbach, MD

*Medical Director & Professor of Nuclear Medicine, University of California Los Angeles*

Dr. Allen-Auerbach is the Medical Director of the Nuclear Medicine Clinic and a Clinical Professor in the Department of Pharmacology/Nuclear Medicine at the University of California Los Angeles. He earned his medical degree from the University of Vienna Medical School. He is board certified by the American Board of Internal Medicine and the American Board of Internal Medicine, Nuclear Medicine.

He is actively involved with clinical trials, speaking at lectures, and supervising postgraduate fellows. His current research interests include investigating the role of molecular imaging with PET/CT to attain deeper knowledge of malignant disease processes and monitoring of cancer treatment. He is an active consultant for MEDQIA in nuclear medicine and a member of the SWOG Imaging Committee. He is published in several journals, including the *Journal of Nuclear Medicine*, *Lancet Oncology*, *British Journal of Cancer*, *European Journal of Nuclear Medicine*, *Scientific Reports/Nature*, and *New England Journal of Medicine*. He has published more than 40 peer-reviewed articles and is the author of many book chapters.

Lowell Anthony, MD, FACP

*Chief, Division of Medical Oncology, UK Markey Cancer Center*

Dr. Anthony earned his undergraduate degree from King College in Bristol, TN, and obtained his medical degree and completed his postgraduate training in medical oncology and clinical pharmacology at Vanderbilt University Medical Center in Nashville, TN. He is board certified by the American Board of Internal Medicine and the American Board of Internal Medicine, Medical Oncology. He is a Fellow of the American College of Physicians. Prior to joining the University of Kentucky, he was a Professor of Medicine at the Louisiana State University Health Sciences Center in New Orleans. Dr. Anthony is an active member of several professional organizations; he has served on committees with the American Society of Clinical Oncology and the American Society of Clinical Pharmacology and Therapeutics. He is a member of the American Association for Cancer Research, American Federation for Medical Research, Southern Society for Clinical Investigation, and a founding member and on the Board of Directors of the North American Neuroendocrine Tumor Society. Dr. Anthony also has been among the “Best Doctors” in the United States for the past 7 years. Dr. Anthony has served as Chairman of the Cancer Committee for the Medical Center of Louisiana Hospital Cancer Program and on the Advisory Board for the General Clinical Research Center. His work has appeared in the *Journal of Clinical Oncology*, *Italian Journal of Gastroenterology*, *Cancer Research*, *Clinical Pharmacology & Therapeutics*, *British Journal of Clinical Pharmacology*, *American Journal of Surgery*, *Journal of Nuclear Medicine*, and the *Annals of Internal Medicine*. He has written and co-authored many book chapters, abstracts, and audiovisual media. He is a reviewer for the *Journal of Nuclear Medicine*, *New England Journal of Medicine*, *Annals of Internal Medicine*, and *Journal of Clinical Oncology*, among other publications. He has also been a guest lecturer at numerous national and international scientific forums.
Joy Ardill, BSc, BD, PhD, MRCPath, FRCPath

*Honorary Professor of Medicine, Queen’s University*

Professor Ardill is an Honorary Professor of Medicine at Queen’s University Belfast. At the end of 2012, she retired as Head of the Regional Regulatory Peptide Laboratory in Belfast Trust and took up an honorary position as Consultant to Research at the Royal Victoria Hospital Belfast NET Group. She was a founding member of the UK and Ireland Neuroendocrine Tumour (UKINET) Society, where she was a committee member for 13 years and authored the biochemical laboratory section of the UKINET Guidelines. Professor Ardill is a member of the Scientific Board of the International Regulatory Peptide Society. She is an active member of the European Organisation for Research and Treatment of Cancer, Quality of Life Group. She has authored more than 100 peer-reviewed publications and has presented data or been a guest speaker at many international and national meetings. She lectures for the medical and science faculties at Queen’s University Belfast and at Trinity College Dublin and has supervised more than 30 postgraduate students for their doctorate degrees. Since 1990, she has become increasingly involved in studying the chemistry of NETs. She recently was an external examiner for thesis at MD University of London 2016 King’s College Subject Neuroendocrine Tumors. Belfast is the regional referral center for NETs and the Regional Regulatory Peptide Laboratory, of which Professor Ardill was head for 23 years, is one of only two such referral laboratories in the United Kingdom. The laboratory facilitates chemical diagnosis and the monitoring of patients with NETs for much of the United Kingdom and all of Ireland. She founded the NET multidisciplinary group in Belfast in 1999 and convened the meetings until 2013. She attends the NET Clinic and has coordinated many of the treatment trials for NET patients in Belfast. She is involved in the assessment of quality of life in patients with NETs and was part of the team that developed the EORTC QLQ NET-21 questionnaire for quality of life in carcinoid patients. She is presently involved in developing a questionnaire for quality of life in functioning pancreatic tumors. Professor Ardill is particularly interested in circulating prognostic indicators for NETs and the possibility of treating not only patient symptoms and tumor bulk but treating circulating chemistry also in an endeavor to improve both outcomes and quality of life.

Bonnie Bennett, BSN, RN

*Registered Nurse, Division of Gastroenterology, University of Pennsylvania Health System*

Bonnie is a dedicated nurse coordinator for the Neuroendocrine Tumor Treatment Program at the University of Pennsylvania, where she coordinates the care of patients with gastroenteropancreatic neuroendocrine tumors and pheochromocytomas/parangliomas. Additionally, she has played an integral role in research, which has been a poster presentation at the NANETS Annual Meeting. Bonnie’s expertise in neuroendocrine tumors is evident as she has most recently served as a moderator at an educational conference and a presenter at the 2016 Oncology Nursing Society Annual Congress. Bonnie is an advisory board member of Lexicon, Novartis, and Carcinoid Cancer Foundation.
Lisa Bodei, MD, PhD

Physician, Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center

Dr. Bodei is a nuclear medicine physician at Memorial Sloan Kettering Cancer Center. She possesses extensive experience and broad expertise in therapeutic and diagnostic application of nuclear medicine in oncology. She was Vice Director of the Nuclear Medicine Division at the European Institute of Oncology, Milan, Italy. She completed her medical degree at the University of Pisa, and stayed on to complete her residency in nuclear medicine at the School of Specialization. At the university, her work focused on investigating clinical applications of \[ ^{123}\text{I} \text{Iepidepride scintigraphy of dopamine D2 receptors in pituitary adenomas, malignant melanoma, and NETs.} \]

Her clinical and research experience has been in theranostics. In 1999, Dr. Bodei was a visiting student at the Department of Nuclear Medicine and Internal Medicine, Erasmus University, Rotterdam, The Netherlands. She returned to Italy in 2000 to take up a fellowship at the Nuclear Medicine Division of the European Institute of Oncology, Milan, with a grant funded by the Italian Association for Cancer Research on Pretargeting and Peptide Receptor Radionuclide Therapy with Beta Emitters. She stayed on at the European Institute of Oncology, becoming Vice Director in 2008. While there, she earned a doctoral degree from the Department of Nuclear Medicine and Molecular Imaging, University of Groningen, The Netherlands, for her work on peptide receptor radionuclide therapy using somatostatin analogs. Dr. Bodei has authored more than 60 articles in international peer-reviewed journals and published 8 invited book chapters, and is currently a reviewer for the Journal of Nuclear Medicine, European Journal of Nuclear Medicine and Molecular Imaging, and Clinical Cancer Research. She has given numerous invited lectures at national and international meetings, and has been on the board of many committees. She is currently Chair of the Radionuclide Therapy Committee of the European Association of Nuclear Medicine (EANM) and a member of the EANM Advisory Board. She is also Chair of the Therapy and Dosimetry Committee of the Italian Association of Nuclear Medicine and Molecular Imaging. In 2012, Dr. Bodei received the distinguished Antonio Venanzi Award from the Italian Association of Neuroendocrine Tumors.

Phillip Boudreaux, MD, FACS

Professor of Surgery, Louisiana State University Health Sciences Center

Dr. Boudreaux is Chairman and Professor of Surgery at the Louisiana State University Health Sciences Center School of Medicine, Department of Surgery and also serves as the Director of Liver/Pancreas Transplant Services. He is board certified in surgery and critical care. Additionally, he holds a specialty certificate in transplant immunology. He is a graduate of Louisiana State University School of Medicine. He completed his internship at St. Jude Children’s Research Hospital in Memphis, TN, and his residency in general surgery at Charity Hospital. He was a fellow at Pittsburgh Children’s Hospital in pediatric surgery and at the University of Minnesota in organ transplantation immunology. His special surgical interests include liver, pancreas, kidney transplantation, organ donation, hepatobiliary and pancreatic surgery, radiofrequency ablation of liver tumors, surgical treatment of NETs, and carcinoids. Dr. Boudreaux is a frequent lecturer at various symposia sponsored by medical organizations such as the American Society of Clinical Oncology and North American Neuroendocrine Tumor Society. He had the
opportunity to establish the first pancreas transplantation clinical programs in Texas at The University of Texas Galveston, and in Louisiana, Ochsner Clinic and Louisiana State University Health Sciences Center.

**Kari Brendtro**

*Former Executive Director, North American Neuroendocrine Tumor Society (NANETS)*

Ms. Brendtro, a NET survivor and patient advocate, was the former Executive Director of the North American Neuroendocrine Tumor Society. She is an active speaker and a paid spokesperson for Novartis. She shares her experience common to many with carcinoid syndrome to help educate others. She has helped write *The North American Neuroendocrine Tumor Society (NANETS) Guidelines: Mission, Goals, and Process* and *Consensus Guidelines for the Management and Treatment of Neuroendocrine Tumors* articles.

**Allen Cohn, MD**

*Oncologist, Rocky Mountain Cancer Centers*

Dr. Cohn is a respected medical oncologist at Rocky Mountain Cancer Centers in Denver, CO. He has more than 3 decades of experience and holds an interest in medical oncology/hematology, carcinoid/NETs, gastrointestinal cancer, neurologic oncology, and drug development. Dr. Cohn specializes in diagnosing and treating carcinoid tumors. He is the recipient of the American Society of Clinical Oncology Clinical Trial Participation Award and 5280 magazine’s “Top Doctor” for oncology. Dr. Cohn received his medical degree from the University of Maryland School of Medicine.

**Arvind Dasari, MD**

*Assistant Professor, Gastrointestinal Medical Oncology, MD Anderson Cancer Center*

Dr. Dasari received his medical degree at Gandhi Medical College in Hyderabad, India. Thereafter, he earned his master’s degree in human genetics and completed his residency in internal medicine at the University of Pittsburgh. He then completed his fellowship in medical oncology/developmental therapeutics at the University of Colorado. His clinical and research interest is in drug development for gastrointestinal cancers, specifically NETs and colorectal cancer. He serves as the principal investigator for several clinical trials and has been published in highly reputable journals including the *Journal of Clinical Oncology* and the *International Journal of Endocrine Oncology*. Dr. Dasari is a member of numerous professional organizations, including the American Society of Clinical Oncology, American Association for Cancer Research, North American Neuroendocrine Tumor Society, National Cancer Institute Neuroendocrine Task Force, and European Neuroendocrine Tumor Society.
Ebrahim Delpassand, MD

Chairman & Medical Director, Excel Diagnostics and Nuclear Oncology Center

Dr. Delpassand is Founder, Chairman, and Medical Director of Excel Diagnostics and Nuclear Oncology Center in Houston. He is also Adjunct Professor at The University of Texas Department of Radiation Oncology and Nuclear Medicine at Baylor College of Medicine. He is the former Deputy Chairman and Chief of Clinical Nuclear Medicine at The University of Texas, MD Anderson Cancer Center, a position that he held for 12 years. He is the principal investigator of several sponsored clinical research trials and FDA-approved investigational projects, including targeted radionuclide therapy, such as Lu-177 Octretate PRRT and Ga-68 Dotatate PET/CT, in patients with neuroendocrine cancers. In January 2006, Dr. Delpassand founded RadioMedix, a biotechnology company with a focus on the development of new targeted radioactive diagnostic and therapeutic agents in the field of oncology. RadioMedix is developing a dotatate kit for PET/CT, alpha radiotherapeutics, and kidney protective agents during PRRT for diagnosis, therapy, and management of neuroendocrine cancers. Dr. Delpassand has authored more than 30 peer-reviewed manuscripts in the field of nuclear medicine, PRRT, and pathology, and lectured in national and international meetings on PET, monoclonal antibody imaging, and therapeutic nuclear medicine.

Laura Devor, MSN, RN, ANP-BC, AOCNP

Nurse Practitioner, Medical Oncology, Rocky Mountain Cancer Centers

Laura attended the University of Colorado, where she earned her bachelor’s degree in biology. Thereafter, she pursued her MSN degree at Vanderbilt University School of Nursing. She has more than 5 years of experience in oncology. Currently, she is a nurse practitioner for oncology outpatients at Rocky Mountain Cancer Centers. Previously, Laura worked in interventional pain management and interventional radiology.

Joseph S. Dillon, MB, BCh, BAO

Associate Professor of Medicine, University of Iowa College

Dr. Dillon received his medical degree at University College, Dublin, Ireland. He then completed his internship and medical senior house officer rotation at St. Vincent’s Hospital. Following his internship, Dr. Dillon completed his residency in internal medicine at the University of British Columbia. He received his training in endocrinology at New England Medical Center, Tufts University Medical School. Thereafter, he became the Director of Tufts University DNA Sequencing Core.

Currently, Dr. Dillon is an endocrinologist at the VA Medical Center and an Associate Professor of Medicine at the University of Iowa College. He is an influential member of the academic community, which is evident in the numerous teaching assignments he has held. He mentors residents for various programs, including internal medicine, neurology, psychiatry, and reproductive endocrinology. He is a member of the Division of Endocrinology Fellowship Program Evaluation Committee and an Assistant Program Director of the Division of Endocrinology.
Fellowship Training Program. Dr. Dillon’s expertise in endocrinology is apparent not only in his academic work but also in research he has published. His research findings have been published in 30 articles. In addition, he has written multiple book chapters and abstracts. Dr. Dillon is an invited lecturer for both national and international conferences. He has been a member of numerous professional organizations, including the American Diabetes Association, the Endocrine Society, American Association for the Advancement of Science, and North American Neuroendocrine Tumor Society.

Enrique Esparza, BS  
**Senior Health Physicist, EH&S/Radiation Safety Program**

Mr. Esparza has been working in health physics for more than 10 years since graduating from the Massachusetts Institute of Technology with a bachelor’s degree in nuclear science and engineering. The first couple of years he spent working for a biotech company that manufactured brachytherapy seeds for prostate cancer treatment. He has spent the past eight years at the University of California Los Angeles (UCLA) Office of Environment, Health, and Safety helping the UCLA campus and UCLA health community work safely with radiation sources, whether in the form of radioactive materials or from radiation-producing machines. Part of keeping the community safe has been to assist the departments, hospitals, and clinics in abiding by the many state and federal regulations. The broad scope of health physics from cyclotrons, shielding, dosimetry, and research around therapies is what makes and keeps him passionate about the field.

George Fisher, MD, PhD  
**Colleen G. Haas Professor of Medicine (Oncology), Stanford University School of Medicine**

Dr. Fisher is the Colleen G. Haas Professor of Medicine at the Stanford Cancer Institute. He is a graduate of Stanford University, where he completed medical school and his residency and oncology fellowship. His research and clinical interests are in drug development and clinical trials applied to gastrointestinal malignancies. He has been the President of the California Division of the American Cancer Society and the recipient of numerous teaching and patient care awards. Dr. Fisher is the Vice Chair of the ECOG-ACRIN GI Committee and is the ECOG liaison to the NCI Task Force on NETs. In addition, he serves on the scientific and medical advisory boards of PANCAN and the Neuroendocrine Tumor Research Foundation, which he co-chairs. He is also an active American Society of Clinical Oncology volunteer and was the chair of the 2016 Gastrointestinal Cancers Symposium.
Joseph Fuselier, MBA

Co-Founder & Member of the Board, Theodent LLC & Assistant Professor, Department of Medicine, Tulane University School of Medicine

Mr. Fuselier attended Louisiana State University, where he received his bachelor of science degree in biochemistry. Thereafter, he earned his master’s degree in business administration in entrepreneurship at Tulane University. Currently, he is Assistant Professor at Tulane University School of Medicine. He is the co-founder of the New Orleans Biotech Networking Group. With his diverse educational background, he prompted the marketing of Theodent. His ability to create innovative pharmaceutical technology made him an indispensable member to Theodent. He specializes in synthetic organic chemistry, peptide/protein chemistry, pharmacology, entrepreneurship, and business, and holds several patents, including in conjugates of therapeutic or cytotoxic agents and biologically active peptides.

Linda Gardner, BSN, RN, VA-BC

Administrative Nurse II, Interventional Radiology, UCLA Health System

Linda is an interventional radiology nurse practitioner with nearly 2 decades of experience. As a clinical nurse at UCLA, she led radiology nursing efforts in the MR Guided Focused Ultrasound Ablation of Uterine Fibroids study. Furthermore, she was the lead nurse for the “Safety and Efficacy of Nurse-Administered Sedation for Radiologic Imaging of Pediatric Patients.” Linda is a member of the Association for Vascular Access and Association for Radiologic & Imaging Nursing. Linda obtained her RN degree from Liverpool John Moores University, United Kingdom, in 1993. She is a recent graduate from Dundee University in Scotland, where she received her BSN degree and will be completing her MSN degree as well.

Pamela Gaytan, RN, BSN

Registered Nurse Clinician, Oncology & Neuroendocrine Specialist, The Neuroendocrine Institute at the Rocky Mountain Cancer Center

Pamela earned her RN degree at Concorde Career College where she was on the Dean’s list and a Lamplighter Student. She then graduated from Western Governor’s University with a BSN degree. As a registered nurse, she developed expert clinical oncology nursing skills with an interest in neuroendocrine cancers. Her focus is on chemotherapeutic/biotherapy agents, surgical interventions, liver-directed and hormone therapies. Pamela is BLS, ACLS, Chemotherapy and Biotherapy certified. She is a member of the Oncology Nursing Society and an advocate for the Healing NET Foundation and Neuroendocrine Cancer Awareness Network. Pamela is a speaker for Ipsen, Lexicon, and Novartis.
Dan Granberg, MD, PhD

**Associate Professor, Senior Consultant, Department of Endocrine Oncology**

Dr. Granberg is a world-renowned physician and a consultant at the Department of Endocrine Oncology, Uppsala Centre of Excellence for endocrine tumors. He is a leading carcinoid and neuroendocrine cancer specialist and has extensive experience in endocrine oncology. His clinical interests are in endocrine tumors, diagnostic procedures, medical therapy, peptide receptor radionuclide therapy, and radioembolization. His research efforts focus on bronchial carcinoids, thymic carcinoids, and development of new diagnostic and therapeutic methods. He has also given many lectures to medical students, doctors, and patients in Sweden and in other countries. He is responsible for the PRRT program with Lutetium-Octreotate at the Department of Endocrine Oncology. He serves as an honorary reviewer for the *Journal of Molecular and Genetic Medicine*. In addition, he has published more than 50 peer-reviewed articles and reviews, and is the author of a number of book chapters on bronchial carcinoids and NETs. He is currently involved in several research projects in the field of NETs, and is the principal investigator in several clinical trials.

Daniel M. Halperin, MD

**Assistant Professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center**

Dr. Halperin is a medical oncologist and clinical investigator at The University of Texas MD Anderson Cancer Center. His clinical and medical interest is developing novel treatments for patients with NETs. He is the primary investigator of numerous clinical trials of new drugs for NET patients. Dr. Halperin works with a laboratory team to further investigate the clinical manifestation of NETs. He earned his bachelor’s degree at the Massachusetts Institute of Technology and his medical degree from Weill Cornell Medical College. Following medical school, he completed his clinical residency in internal medicine at Brigham and Women’s Hospital. Thereafter, he completed his fellowship in oncology at MD Anderson Cancer Center. He is a recipient of multiple awards, including the Waun Ki Hong Award for Clinical Investigation. He is a member of the American Society of Clinical Oncology and the North American Neuroendocrine Tumor Society.

Anthony Heaney, MD, PhD

**Associate Professor, David Geffen School of Medicine at the University of California Los Angeles**

Dr. Heaney is Associate Professor at the David Geffen School of Medicine at the University of California Los Angeles (UCLA). He graduated in 1987 from Queen’s University of Belfast, Northern Ireland, and earned his PhD degree from Queen’s University. He then completed his internship in internal medicine and surgery at Mater Infirmorum Hospital in Belfast, followed by an internal medicine, neurology, endocrinology, diabetes, and metabolism residency at Royal Victoria Hospital in Belfast. On completion of his endocrinology, diabetes, and metabolism research
fellowship at Royal Victoria Hospital, he was appointed honorary lecturer in diabetes and endocrinology at the University of Manchester. His clinical and research interests focus on the pathogenesis of pituitary tumors and exploiting novel molecular targets to develop innovative treatments for pituitary tumors and other NETs. His current research investigates in vitro and in vivo effects of dietary sugars in cancer development and progression. He has authored a multitude of articles for such peer-reviewed publications as The Journal of Clinical Investigation, Nature Medicine, Clinical Endocrinology, and Pituitary. Dr. Heaney has composed book chapters for Bailliere’s Clinical Endocrinology and Metabolism, Oxford Textbook of Endocrinology, and Endocrine Updates. He is a member of the editorial boards for The Journal of Clinical Investigation, Cancer Research, and The Journal of Clinical Endocrinology & Metabolism. Dr. Heaney is a Fulbright Scholar and a fellow of the Royal College of Physicians (United Kingdom). He has been elected membership in several professional organizations, including the Endocrine Society, the Pituitary Society, and the Society of Endocrinology. He was voted Best Doctor 2009-2010, 2014. He is affiliated with Ronald Reagan UCLA Medical Center and Santa Monica UCLA Medical Center.

Randolph Hecht, MD
Professor, Department of Medicine & Gastrointestinal Oncology Director, UCLA Gastrointestinal Oncology Program

Dr. Hecht attended Eastern Virginia Medical School in 1984 and completed his internship and residency at Northwestern University Feinberg School of Medicine. He pursued his fellowships in gastroenterology and oncology at the University of California Los Angeles (UCLA). He has more than 2 decades of experience and is internationally known for his clinical and translational research in gastrointestinal cancers. Both his clinical and research interests are in the treatment of NETs of the gastrointestinal tract. He has published and presented on molecular biology, early detection, and treatment of gastrointestinal malignancies. His current research focus is on preclinical models of therapy with biological agents, early studies with gene therapy vectors and tyrosine kinase inhibitors, and leading phase 2 and phase 3 trials with novel agents. Dr. Hecht is Professor of Hematology/Oncology and the Gastrointestinal Oncology Director at UCLA. He is also affiliated with St. John’s Health Center. He holds the Carol and Saul Rosenzweig Chair for Cancer Therapies Development and is a member of the American Society of Clinical Oncology.

Andrew Hendifar, MD, MPH
Medical Director, Pancreatic Cancer, Samuel Oschin Comprehensive Cancer Institute & Assistant Professor/Medical Oncology Lead, Cedars-Sinai Medical Center

Dr. Hendifar graduated with a medical degree and a master’s degree in public health from the Tulane University School of Medicine in 2003. He then trained in hematology and medical oncology, completing his requirements in 2011. During that time, he spent 3 years as a Fellow (Chief) of Hematology and Oncology at the University of Southern California. After completing his board certification requirements, he spent 2 years as the primary investigator of a phase 1 study at the Sarcoma Oncology Center. Currently, he is the primary investigator for several studies that investigate radioimmunotherapy for neuroendocrine and pancreatic cancer. His research interests focus on developing new
therapies for pancreatic cancer and NETs. His groundbreaking research efforts have aided in the development of a treatment protocol in pancreatic cancer cachexia. Dr. Hendifar is the present Medical Oncology Lead for the Gastrointestinal Disease Research Group at Cedars-Sinai and Co-Director of Pancreas Oncology. He is a member of numerous organizations, such as End of Life, Multi-Disciplinary Neuroendocrine Team, Pharmacy & Therapeutics Committee, Cancer Committee, Internal Review Board, and Multi-Disciplinary Pancreatic Cancer Team. In addition, he serves as the Course Director of the Los Angeles Carcinoid Neuroendocrine Tumor Society and the Caring for Carcinoid Foundation. Dr. Hendifar’s expertise is evident in the numerous awards he has received. He is actively involved in many teaching activities, lecturing, and mentoring students.

Ken Herrmann, MD, MBA
Chairman of the Department of Nuclear Medicine, Universitätsklinikum Essen, Germany
Dr. Herrmann received his medical degree at Humboldt University, Berlin, Germany. In 2007, he completed his medical thesis, which investigated the expression and function of A1 adenosine receptors in gliomas. He completed his research fellowship at Hokkaido University in Japan. He is board certified in nuclear medicine in Germany. He is a member of the Society of Nuclear Medicine and Molecular Imaging, Oncology Committee Member of European Association of Nuclear Medicine, Imaging Group Member of the European Organisation for Research and Treatment of Cancer, and DRG Committee Member of the German Society of Nuclear Medicine. He is the author of numerous book chapters on nuclear medicine. In addition, he is the primary author of Radioguided Surgery: Current Applications and Innovative Directions in Clinical Practice. Dr. Herrmann is an active reviewer of countless medical journals, including the Journal of Nuclear Medicine, British Journal of Cancer, European Journal of Nuclear Medicine and Molecular Imaging, and the International Journal of Molecular Sciences. He has been a prominent lecturer and oral speaker at many conferences. Furthermore, he is an active participant in mentoring residents and an active participant in clinical trials and research at his institution. Dr. Herrmann is the recipient of several awards and honors, including an award for Best Clinical Paper published in the Journal of Nuclear Medicine.

Timothy Hobday, MD
Medical Oncologist, Assistant Professor & Advanced Oncology Fellowship Director, Mayo Clinic Hospital
Dr. Hobday is Associate Professor of Oncology and Advanced Oncology Fellowship Director at the Mayo Clinic Hospital. He is a practicing oncologist and researcher with more than 20 years’ experience in the area of breast cancer and neuroendocrine carcinoma. His research focuses on chemotherapy agents combined with novel targeted therapies for patients with NETs and breast cancer. He conducts clinical and translational research in NETs. He has been the primary investigator on several multicenter clinical trials that have explored novel therapies for NETs. He has published more than 50 journal articles and lectured at numerous symposia and conferences.
Ronald Hollander, MPH

Executive Director, Neuroendocrine Tumor Research Foundation & Adjunct Assistant Professor, Public Health Department, Tufts Medical School

Mr. Hollander is the Executive Director of the Neuroendocrine Tumor Research Foundation (NETRF) and Adjunct Assistant Professor at Tufts Medical School teaching health policy in the Public Health Department. Prior to his role as Executive Director, he was formerly the President and CEO of the Massachusetts Hospital Association. In addition, he was Director of Corporate Planning for Children’s Hospital in Boston. In his earlier career years, he served as a consultant for health and social systems, followed by public service as a systems analyst. He serves as an independent consultant, specializing in The Reform Exchange for a variety of multistakeholder groups. He has focused his efforts on continuing to develop the success of NETRF and its research goals that can lead to a cure. He is a prominent member of communities affected by NETs by providing support and education. He serves on numerous boards and committees, including the Governor’s Commission on Health Care Reform, the Legislative Special Commission on Uncompensated Care, the Governor’s Commission on Managed Care, the American Hospital Association (AHA)’s Strategic Long-Range Planning Committee, and AHA’s Task Force on Medicaid Reform. He is a notable speaker and lectures about the future of healthcare, quality and patient safety, and healthcare reform. He earned his bachelor’s and MPH degrees at the Massachusetts Institute of Technology.

Giovanna Imbesi, MBA

Executive Director, Los Angeles Carcinoid Neuroendocrine Tumor Society (LACNETS)

Ms. Imbesi is a NET survivor, patient advocate, and Executive Director of the Los Angeles Carcinoid Neuroendocrine Tumor Society (LACNETS). She is a composer, classically trained pianist, and producer. She has toured and performed with Dave Koz, Yanni, Anita Baker, Andy Summers from The Police, and many others. In 2006, after recovering from carcinoid cancer surgery, she composed the song “Hush.” As a believer in the power of music to heal, she donated the song “Hush” to Songs for Life to help raise awareness to carcinoid and NETs. She earned her master’s degree in business administration in 2013 at the University of California Anderson School of Management.

Mark Kidd, PhD

Laboratory and Scientific Director, Wren Laboratories LLC

Dr. Kidd has more than 15 years of specialized experience in the laboratory focused on the molecular and cancer biology of NETs. He has focused his professional and academic research on the biology of neuroendocrine cells and the development of tumor models of the disease. He has published 3 books, more than 30 book chapters, and over 200 papers. His publications have investigated various areas, including the development of NET tissue microarrays, tumor biology, global gene analysis, and gastric/pancreatic pathology. Dr. Kidd’s expertise in NETs is
evident in the professional services he provides and research he has published. He has served as a moderator for multiple scientific meetings at Digestive Disease Week and the European Society for Clinical Investigation. Additionally, he has presented at numerous lectures, both internationally and nationally. He is a council member of the American Gastroenterological Association and was a group leader for the European Hepato-Pancreato-Biliary Association. He is an active member of numerous associations such as the American Association of Cancer Research, American Society of Clinical Oncology, Association for Molecular Pathology, Endocrine Society, North American Neuroendocrine Tumor Society, Yale Stem Cell Center, and Yale Cancer Center. He is a reviewer for multiple journals, including *The American Journal of Gastroenterology*, *European Journal of Endocrinology*, and *European Journal of Nuclear Medicine and Molecular Imaging*. Prior to joining Wren Laboratories LLC as Laboratory and Scientific Director, Dr. Kidd taught and mentored dozens of surgical residents, medical students, and undergraduates. He received his bachelor’s degree and doctoral degree at the University of Cape Town. He is credentialed with the American Board of Clinical Chemistry in Molecular Diagnostics.

**Michelle Kim, MD, PhD**

_Director, Center for Carcinoid and Neuroendocrine Tumors, Associate Professor of Medicine, & Associate Director of Endoscopy, Mount Sinai School of Medicine_

Dr. Kim is Director of the Center for Carcinoid and Neuroendocrine Tumors, Associate Professor of Medicine, and Associate Director of Endoscopy at Mount Sinai. She earned her undergraduate degree from Harvard College and her medical degree from Stanford University School of Medicine. She completed her postgraduate training in internal medicine and gastroenterology at New York Presbyterian Hospital (Cornell). Dr. Kim is board certified by the American Board of Internal Medicine and American Board of Internal Medicine, Gastroenterology. She is well known for her ability to mentor dozens of medical students, residents, and gastroenterology fellows. This is evident in the multiple teaching awards that she has received. Under her direct supervision, many of her students have successfully published manuscripts and have become junior faculty members at other academic institutions. Dr. Kim is an active member of numerous committees and an active reviewer of multiple professional journals. She has published more than 40 publications in journals such as the *Journal of Clinical Oncology* and *Gastroenterology*. She has lectured nationally and internationally on carcinoid and NETs. In addition, she is well known for her expertise as an endosonographer. She is nationally renowned for her work in translational and epidemiologic approaches in assessing outcomes in patients with carcinoid and NETs. Dr. Kim has spent her clinical career working along with Dr. Richard R.P. Warner in caring for patients with uncommon gastrointestinal cancers. She acquired leadership skills while serving as President of the New York Society for Gastrointestinal Endoscopy (NYSGE). During this experience, she was involved in the leadership of a 20-member Executive Council, strategic and financial planning, and overseeing of the NYSGE Annual Course.
Angela Laffan, MS, NP
*Nurse Practitioner & Assistant Director, Gastrointestinal Oncology Survivorship Program, UCSF Medical Center*

Angela has more than 25 years of experience in oncology nursing. She specializes in cancer survivorship and helps patients manage side effects from gastrointestinal cancer and its treatments. Additionally, she educates patients on a variety of tools and resources to help improve their health, quality of life, and reduce their risk of cancer recurrence. She is a member of the Oncology Nursing Society and a frequent lecturer. Angela is an Australian native and earned her BSN degree from Deakin University. Thereafter, she received her master’s degree from UCSF’s adult nurse practitioner program, with a minor in integrative medicine. Angela is affiliated with numerous hospitals, including UCSF, Mills-Peninsula Health Services, and Sequoia Hospital.

Eric Liu, MD
*Co-Director, The Neuroendocrine Institute at Rocky Mountain Cancer Center and HealthONE*

Dr. Liu is a surgeon specializing in NETs and related diseases. He attended Harvard and Columbia universities and trained in surgery at New York-Presbyterian Hospital. He also received specialty training in NETs at Uppsala University, Uppsala, Sweden, under the tutelage of Kjell Oberg, MD, PhD. Dr. Liu developed a specialty neuroendocrine center at Vanderbilt University, Nashville, TN, where he served as Assistant Professor of Surgery and Radiology, and received a master’s degree in clinical investigation. Dr. Liu was the first investigator to open a clinical trial and perform the 68 Gallium-Dotatate PET/CT scan for NETs in the United States. In June 2015, he joined Allen Cohn, MD, at the Rocky Mountain Cancer Centers (RMCC) in Denver and became Co-Director of The Neuroendocrine Institute at RMCC and HealthONE. He performs complex and general surgery for NETs, as well as manages complicated issues such as refractory ascites and carcinomatosis. He is responsible for all general surgery for neuroendocrine patients and works in a multidisciplinary team. He is also Co-Founder of The Healing Net Foundation, and serves as chief medical advisor for the 501c(3) organization, which aims to provide support to the healthcare professionals who treat NETs and promote advocacy for neuroendocrine patients.

Cindy Lovelace
*Co-Founder & Executive Director, The Healing NET Foundation*

Ms. Lovelace has more than 30 years of experience in media, marketing, promotions, and event management. She was a former news reporter, anchor, and promotions director at WKDF and WGFX. In 2013, she utilized all these skills and founded The Healing NET Foundation after being diagnosed with a NET. She was the recipient of the Hero of Hope Patient Award from the Academy of Oncology Nurse & Patient Navigators. She attended Morehead State University, where she received her bachelor’s degree in radio/TV communications and art.
Joshua Mailman, MBA  
*President, NorCal CarciNET Community*

Mr. Mailman is President of the NorCal CarciNET Community and Chair of the Patient Advocacy Advisory Board for the Society of Nuclear Medicine and Molecular Imaging. He holds a bachelor’s degree in economics and a master’s degree in business administration in marketing and finance from the University of California Los Angeles. He co-created eFax.com and served as vice president of operations. He holds several patents for his work on eFax’s technology. After being diagnosed with a NET in 2006, he has redirected his focus in the nonprofit community. He was featured in the Society of Nuclear Medicine and Molecular Imaging’s *Clinical Trials Pathways* newsletter in 2014. He is a member of the NCI Task Force for NETs.

Lorrie McSherry, BSN, RN, OCN  
*Assistant Director of Nursing, North Shore Hematology/Oncology Associates*

Lorrie graduated from Northeastern University, Boston, MA. Since then she has developed extensive experience in hospital, clinical, and corporate settings. She has spent the past 17 years of her clinical career specializing in hematology/oncology. Lorrie was a consultant on multiple pharmaceutical advisory boards such as Ipsen, Gilead Sciences, Genentech, and AMAG Pharmaceuticals. She is a member of the Oncology Nursing Society, American Nurses Association, Infusion Nurses Society, and Who’s Who Among American Nurses.

David Metz, MD  
*Professor of Medicine, Hospital of the University of Pennsylvania*

Dr. Metz is Professor of Medicine and Associate Chief for Clinical Affairs in the Division of Gastroenterology at the University of Pennsylvania in Philadelphia, where he is Director of the Acid-Peptic Disease Program and Co-Director of the GI Physiology Laboratory, the Swallowing Disorders Program, and the NET Program. He is actively involved in clinical research, patient care, and teaching of students, residents, and fellows. His clinical research program is particularly active in acid-peptic conditions, including hypersecretory states such as Zollinger-Ellison syndrome, *Helicobacter pylori* infection, nonsteroidal anti-inflammatory drug gastropathy, and gastroesophageal reflux disease. He also has particular expertise in the diagnosis and management of patients with functional and nonfunctional NETs of the pancreas and alimentary tract. He has been a principal investigator on several trials evaluating upper gastrointestinal disease states. He is also active in national gastroenterology societies and was a prior member of the Liaison Committee for Recertification of the American Board of Internal Medicine (American Gastroenterological Association representative) and the FDA Gastrointestinal Drugs Advisory Committee. He is chair of the North American Neuroendocrine Tumor Society.

Dr. Metz earned his MBBCh (MD equivalent) degree from the University of the Witwatersrand in Johannesburg, South Africa. He moved to the United States in 1986 and pursued a residency in internal medicine at the Albert Einstein Medical Center in Philadelphia, PA. He completed a fellowship in gastroenterology in Washington, DC, in
the combined Georgetown/Veterans Affairs Medical Center/National Institutes of Health (NIH) program. He remained on staff at the NIH for 2 more years as a senior staff fellow, performing basic research in pancreatic acinar cell secretion and clinical research in Zollinger-Ellison syndrome specifically. In 1993, Dr. Metz moved to Philadelphia in the role of Assistant Professor in the clinician educator track at the University of Pennsylvania. He was promoted to Associate Professor in 1998 and Full Professor in 2003.

Charles Nutting, DO  
**Radiologist, Radiology Imaging Associates (RIA)**

Dr. Nutting is a board-certified, fellowship-trained interventional radiologist. He specializes in performing minimally invasive image-guided procedures to treat liver cancer and vein disorders. Currently, he practices at Radiology Imaging Associates (RIA), where he provides innovative liver cancer therapies. In addition, he is Chief of Interventional Radiology at Sky Ridge Medical Center. When he is not practicing at RIA, he is treating endovascular disease, vein disorders, and cancer at local and regional hospitals throughout the Rocky Mountain region. He is world renowned for the interventional treatment of liver cancer and offers leading-edge procedures, including chemoembolization, radiofrequency ablation, and selective internal radiation therapy (SIRT). He was the first physician to perform liver radioembolization with Sir-Sphere in the United States. Since his initial radioembolization procedure, he has performed more than 900 procedures and teaches SIRT procedures using Y90 internal radiation beads nationwide. Dr. Nutting is regularly invited to present at conferences both nationally and internationally. He has authored multiple articles that have been published in various medical journals. He is the chairman of several professional committees that help to establish guidelines and best practices, such as the Practice Development Subcommittee. He is also a Fellow of the Society of Interventional Radiology. In 2015, he was recognized as “Best Doctor” in the *Denver Business Journal*. He is the recipient of numerous awards and honors, including a recent humanitarian award for his work with cancer patients. He is an accomplished researcher and is regularly asked to lead clinical trials.

Kjell Oberg, MD, PhD  
**Professor, Department of Endocrine Oncology, Uppsala University Hospital**

Dr. Oberg is a renowned NET cancer specialist and the former head and founder of the Department of Endocrine Oncology from Uppsala University Hospital. He possesses more than 40 years of experience in the field of NETs and has filled a variety of roles. In 1986, Dr. Oberg became Clinical Associate Director of the Ludwig Institute for Cancer Research. He became Chairman of the Department of Medical Sciences at the Medical Faculty of Uppsala University in 1998. By 2002, he was Dean of the Medical Faculty. He was a member of the Centre of Excellence for Endocrine Tumors and Vice Chairman of the Department of Endocrine Oncology at University Hospital, Uppsala. Currently, he is Senior Advisor and Senior Professor at the Department of Medical Sciences, Uppsala University. He was one of the founders and coordinators of the European Neuroendocrine Tumor Network.
(ENET). Additionally, he was the past Chairman of the Nordic Neuroendocrine Tumor Group. He spearheaded the treatment of carcinoid tumor patients with interferon and somatostatin analogs. Dr. Oberg developed assays for tumor markers such as chromogranin A and radiologic procedures, including specialized PET scan. He is currently leading the first study in men of an oncolytic virus for NETs patients. Dr. Oberg was the first physician to describe a genetic deletion in multiple endocrine neoplasia type 1. He is an accomplished lecturer and has given hundreds of presentations at international meetings. He has published more than 500 papers within his research field and has over 14,850 citations. Additionally, he is the author of numerous chapters on carcinoid tumors in several international textbooks, including Williams Textbook of Endocrinology and Clinical Endocrinology. He is the recipient of multiple awards and honors, such as the European Interferon Research Award, European Gold Medal in Endocrinology from the English Endocrine Society, the Harry Boström Award Lecture at the Swedish Medical Society, the University Hospital Clinical Research Award, Rudbeck Medallion for Excellence in Research, and the Lifetime Achievement Award from the North American Neuroendocrine Society. He was awarded “Eminent Scientist of the Year 2003” by the International Research Promotion Council and World Scientist Forum. Dr. Oberg is a member of several national and international professional organizations, including the Royal Society of Sciences, Swedish Society for Medical Research, NANETS Advisory Board, and Finnish Endocrine Society. Dr. Oberg was the 2012-2014 President of ENETS and also an honorary member of Spanish Neuroendocrine NET-work, and Finnish Oncology Society.

Sue O’Dorisio, MD, PhD
Professor of Pediatrics & Pediatric Fellowship Director, Department of Hematology/Oncology, University of Iowa

Dr. O’Dorisio graduated with a bachelor of science degree in biology and mathematics from Creighton University in Omaha, NE. She later earned her doctoral degree in biochemistry from the University of Nebraska. She furthered her education and attended The Ohio State University, where she earned her medical degree, completed her residency in pediatrics, and completed her fellowship in pediatric hematology/oncology. Dr. O’Dorisio is currently the University of Iowa Distinguished Professor of Pediatrics. Her research has focused on pharmacologic and molecular characterization of G protein, the epidemiology of NETs in children, and theranostics for NETs. Children and young adults with neuroblastomas, medulloblastomas, and NETs have become her clinical focus. Her passion to mentor graduates, medical students, as well as MD and PhD fellows in NETs is evident in the University of Iowa Distinguished Mentor Award she received in 2015. She has published more than 150 peer-reviewed articles and has provided research support for additional publications involving various topics related to NETs in children. Since 1976, she has been a National Institutes of Health–funded investigator. She is currently studying the role of vasoactive intestinal peptide and somatostatin in neural development using transgenic and knockout mice. Dr. O’Dorisio believes that this new understanding of the role of neuropeptides in neural crest development should allow for the development of new diagnostic and therapeutic options for children with neuroblastoma and medulloblastoma. Dr. O’Dorisio is also the principal investigator on the SPORE trial.
Thomas O’Dorisio, MD  
Co-Leader Gastrointestinal Neuroendocrine MOG, Professor, Internal Medicine, University of Iowa  

Dr. O’Dorisio received his medical degree from Creighton University and completed both his fellowship and residency at the Ohio State University. He has more than 40 years of experience as a professor and endocrinologist, working in a variety of roles, including Director of the Division of Endocrinology, Associate Director of Clinical Research Center & Supervisor, Core Peptide Lab, and Director of Special Endocrine Lab at The Ohio State University. He is currently Professor of Internal Medicine at the University of Iowa Carver College of Medicine. In his work at the University of Iowa Neuroendocrine Cancer Clinic, Dr. O’Dorisio collaborates with a multidisciplinary team of physicians and caregivers in the treatment of patients with neuroendocrine cancer. Dr. O’Dorisio and his team create tailored treatment strategies that cater to the individual needs of each patient. His research focuses on the medical management of and dynamic treatment modalities for neuroendocrine cancer, diabetes mellitus, and endocrine cancers (predominantly thyroid cancer). He is the recipient of numerous awards and has authored more than 200 papers and multiple book chapters. He is a member of multiple professional organizations, including the Endocrine Society, American Gastroenterological Association, Society of Nuclear Medicine, and American Association for Cancer Research. Dr. O’Dorisio also serves on the NANETS Board of Directors.

Richard Parker, MD  
Thoracic Surgeon, Cardiothoracic Surgery Associates  

Dr. Parker graduated from the University of Nebraska College of Medicine in 1968. He completed his internship at Denver Health Medical Center and residency at the University of Colorado Health Sciences Center. He completed his fellowship at the Mayo Graduate School of Medicine. He is board certified in general, thoracic, and cardiovascular surgery. Currently, he serves as a thoracic surgeon at Cardiothoracic Surgery Associates, Chief of Cardiovascular Surgery at Rose Medical Center, and Chairman of the Department of Cardiovascular Surgery at Presbyterian/St. Luke’s Medical Center. He also served as a physician at Colorado Cardiovascular Surgical Associates prior to joining HealthONE. He has extensive experience in all aspects of thoracic surgery, coronary artery surgery, and aortic and mitral valve surgery. Dr. Parker spearheaded minimal access video-assisted thoracoscopic surgery of the chest. He has co-authored multiple papers and presented research at widely known conferences and seminars. For the past 20 years, he has been named one of 5280 magazine’s “Best Doctors.”
A. Scott Paulson, MD

Medical Oncologist, Texas Oncology-Baylor Charles A. Sammons Cancer Center

Dr. Paulson is board certified in medical oncology and internal medicine at Texas Oncology-Baylor Charles A. Sammons Cancer Center. He graduated with honors from The University of Texas Southwestern Medical School at Dallas in 2008. Having more than 9 years of diverse experiences in medical oncology and internal medicine, Dr. Paulson is affiliated with Baylor University Medical Center, and cooperates with other doctors and specialists at the Texas Oncology PA medical group. Dr. Paulson’s specialty is in gastrointestinal cancer. He is Associate Medical Director of the Gastrointestinal Oncology Research Committee and Pathways Task Force Committee. He also serves as Medical Director at the Neuroendocrine Research and Treatment Center.

Alexandria T. Phan, MD, FACP

Founder and Managing Member, Phan & Associates LLC, Professor & Medical Oncologist-Hematologist, Houston Methodist Institute of Academic Medicine

Dr. Phan is recognized as a world expert in adrenal and neuroendocrine cancers. She specializes in gastrointestinal (GI) cancers as well as rare endocrine cancers. She has treated more than 500 carcinoid/NET patients over the span of her medical career. Her most recent tenure includes 12 years as Associate Professor at MD Anderson, where she has mentored fellows and residents. In 2013, Dr. Phan joined the Houston Methodist Cancer Center as head of GI Oncology to lead and develop Houston Methodist’s GI and rare cancers program, including a multidisciplinary team to care for NET cancer patients. She is also affiliated with CHI St. Luke’s Hospital and Texas Medical Center. Dr. Phan is the Founder and Managing Member of Phan & Associates LLC, where she is a GI medical oncologist and expert consultant for NET and rare malignancies. She has earned multiple educational awards from residency and fellowship training programs, as well as from various cancer institutions. Dr. Phan has extensive experience with clinical trials in carcinoid and NETs, and her current research is a collaboration with the Houston Methodist Research Institute on several projects, including targeted/novel imaging for NET, patient-derived xenografts for GI and neuroendocrine cancers, as well as patient quality-of-life outcomes. Her clinical interest focuses on upper GI malignancies, adrenal malignancies, and NETs. She is a member of multiple organizations, including, but not limited to, the American Association of Clinical Research, American Joint Committee on Cancer, American Society of Clinical Oncology, American Society of Hematology, and European NET Society. Dr. Phan earned her bachelor of science degree in biochemistry from the University of California. Afterwards, she graduated from the University of California College of Medicine. At Baylor College of Medicine, Dr. Phan completed her residency in internal medicine and her fellowship in hematology. She also completed an additional fellowship in oncology at The University of Texas MD Anderson Cancer Center.
Philip Philip, MD, PhD, FRCP  
*Professor & Medical Oncologist, Wayne State University School of Medicine & Karmanos Cancer Institute*

Dr. Philip serves as the Kathryn E. Cramer, M.D., Endowed Professor in Cancer Research and is leader of the Gastrointestinal and Neuroendocrine Multidisciplinary Team at the Barbara Ann Karmanos Cancer Institute in Detroit, MI. He also serves as Professor of Oncology and Pharmacology at Wayne State University School of Medicine (WSU SOM), Detroit, as well as Vice President for Medical Affairs at Karmanos. He earned his medical degree at the University of Baghdad College of Medicine in Iraq and his doctoral degree in clinical pharmacology and pharmacogenetics at the University of London Guy’s Hospital Medical School in the United Kingdom. Dr. Philip completed his residency at the University of Baghdad. He pursued his fellowship in medical oncology at the University of Oxford and MD Anderson Cancer Center in Houston. He is board certified in medical oncology in the United States and a Fellow of the Royal College of Physicians in the United Kingdom. He joined Karmanos in 1995 and is also affiliated with DMC Detroit Receiving Hospital and Harper University Hospital. Dr. Philip is a member of the Pancreatic Cancer Action Network’s Scientific Advisory Board. He also chairs the Pancreatic Cancer Committee at the Southwest Oncology Group and is a member of the International Liver Cancer Association and the American Society of Clinical Oncology. He has earned numerous awards, including the Wayne State University Medical School Teaching Award and Best Doctors of America. His major research interests are in the development of new therapies for gastrointestinal and neuroendocrine cancers with a special focus on pancreatic cancer. He has been the principal investigator on numerous clinical trials in gastrointestinal cancers. A frequent national and international lecturer, Dr. Philip has authored more than 200 manuscripts, review articles, and editorials, and co-edited a book on pancreatic cancer. His lecture topics include pancreatic and biliary cancer; NETs; and gastroesophageal cancer.

Anita Piano, MSN, RN, VA-BC  
*Clinical Educator & QI Specialist, Interventional Radiology, UCLA Health System*

Anita earned her bachelor’s degree in 2002 at the University of Nevada and her MSN degree in 2014 at Mount St. Mary’s College. She had spent nearly a decade of her clinical career devoted to adult intensive care before transitioning to interventional radiology. Anita joined the UCLA Health System, where she gained vascular access and interventional radiology experience. There she was cross-trained to the Pediatric PICC Service. She managed the PICC Service, where she then developed the program in a second hospital. In 2011, she became manager of the adult and pediatric team. Currently, she holds the position of Clinical Educator and QI Specialist of Interventional Radiology at UCLA Health System.
Robert Ramirez, DO, FACP
Medical Oncologist, Ochsner Medical Center

Dr. Ramirez earned his medical degree from the University of Medicine and Dentistry of New Jersey School of Osteopathic Medicine. He completed his residency in internal medicine at Cooper University Hospital in Camden, NJ, and his fellowship (Chief Fellow) in hematology/oncology at the University of Tennessee Health Sciences Center in Memphis. He is board certified in medical oncology and internal medicine. Dr. Ramirez is a Fellow of the American College of Physicians and a member of the American Society of Clinical Oncology, the International Association for the Study of Lung Cancer, and the North American Neuroendocrine Tumor Society. His clinical and research interests are in lung cancer, specifically non–small-cell and small-cell cancers as well as NETs of the lung, including diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH), typical and atypical carcinoids. Dr. Ramirez has given multiple presentations at national and international meetings on the topics of lung cancer and NETs, and has published multiple peer-reviewed publications. He splits his clinical and research duties between the Ochsner Lung Cancer Multidisciplinary Program and the Ochsner Kenner/LSU Multidisciplinary Neuroendocrine Clinic. He is active in clinical trial design as well as teaching to fellows, residents, and medical students. Dr. Ramirez’s clinical interests include non–small-cell lung cancer, small-cell lung cancer, NETs of the lung, DIPNECH, and NETs of the gastrointestinal tract.

Pam Ryan, BSN, RN
Nurse Manager, Oncology Services & Infusion Center, Ochsner Medical Center–Kenner

Pam spent nearly a decade of her early clinical years gaining experience in the intensive care unit at Mercy and Baptist Health Corporation. She then transferred to transplant services as Nurse Manager and Transplant Coordinator. Currently, Pam holds the position of Nurse Manager in the Oncology Services & Infusion Center at Ochsner Medical Center–Kenner. Since joining Ochsner, she has served as a navigator for all new neuroendocrine tumor (NET) patients at the clinic. She has hosted and co-coordinated several of the National NET Patient Conferences, including the most recent 2016 conference. Pam has coordinated build-out and opened infusion center service lines, where she demonstrated a 10% growth annually in both the NET clinic and infusion center. Pam’s dedication to her work is evident through her active participation in presentations, publications, community service, and advisory boards. In 2009, she was the recipient of the Great 100 Nurses Award.
Walid Shaib, MD

*Assistant Professor, Department of Hematology and Medical Oncology, Winship Cancer Institute at Emory University School of Medicine*

Dr. Shaib earned his medical degree from the American University of Beirut. He completed his residency in internal medicine at Yale New Haven Hospital. Following his residency, he completed his fellowship in hematology and medical oncology at Winship Cancer Institute of Emory University. He remained at Winship Cancer Institute as a Chief Fellow in Medical Oncology. Currently, he is Assistant Professor in the Division of Gastrointestinal Oncology and Hematology Oncology at Winship Cancer Institute. Additionally, he holds a position with Veterans Affair Emergency Room Privileges. Dr. Shaib’s findings have been published in numerous articles. He is a prominent lecturer and actively involved in mentoring medical students, residents, and fellows. He is a member of the Institutional Review Board, Gastrointestinal Mentoring Committee, and Phase I Clinical Trial Committee. Dr. Shaib is a member of the American Society of Clinical Oncology and American Society of Hematology.

Michael Soulen, MD

*Professor, Department of Radiology & Surgery, Hospital of the University of Pennsylvania*

Dr. Soulen graduated from the University of Pennsylvania Medical School and completed his residency at Johns Hopkins Hospital. His clinical research and fellowship was completed at Thomas Jefferson University Hospital. He is board certified in vascular and interventional radiology and diagnostic radiology. He is Professor of Radiology and Surgery at the University of Pennsylvania. His research areas of interest include anal cancer, angiomyolipoma, angioplasty, bile duct tumors, biliary strictures, gastrointestinal carcinoid tumors, interventional radiology, kidney cancer, leg pain, liver cancer and metastases (secondary liver cancer), lung tumors, renal artery disease, and vascular disease/medicine. His clinical expertise includes interventional radiology, interventional oncology, chemoembolization, embolization, and tumor ablation. He is affiliated with the Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center. Dr. Soulen is recognized annually in *Philadelphia Magazine*’s Top Docs issue from 2004 through 2016; he has also been recognized by *America’s Top Doctors* throughout the years. He is a member of multiple associations, including the American College of Radiology, American Heart Association, Cardiovascular and Interventional Radiology Society of Europe, International Liver Cancer Association, and North American Neuroendocrine Tumor Society.
Sarah Smith, RN, BSN

Registered Nurse, Texas Oncology, P.A.

Sarah recently joined the medical field as a registered nurse in 2014 after graduating from Baylor University Louise Herrington School of Nursing. She began her medical career in 2011 as a medical assistant at Texas Oncology, P.A., before transitioning into nursing school. After completing her bachelor’s degree in nursing, she began working at UT Southwestern Medical Center, Clements University Hospital as a registered nurse in the Bone Marrow Transplant Unit. Currently, Sarah returned to her roots at Texas Oncology, where she works as a registered nurse. She is a member of the Oncology Nursing Society.

Dana Stafford, RN

Clinical Nurse, Multidisciplinary Clinic, University of Kentucky

After receiving her associate’s degree in nursing, Dana began her clinical experience in the Markey Cancer Center Oncology Unit. She spent a decade working in the oncology unit before transitioning into radiation medicine. Currently, Dana works as a clinical nurse in the Multidisciplinary Clinic at the University of Kentucky. She was a Markey Council representative for nearly half a decade and was a member of the Distress Screening Workflow Committee and SCM Documentation Committee. Dana’s commitment is apparent from the most recent award she received in 2016, the Markey Difference Maker Quarterly Award.

Laura Tang, MD, PhD

Pathologist, Memorial Sloan Kettering Cancer Center & Professor of Pathology, Weill Cornell Medicine

Dr. Tang is a pathologist at Memorial Sloan Kettering Cancer Center who is trained in gastrointestinal (GI) surgical pathology and as a basic scientist with a focus on molecular pathophysiology of the GI tract. She recently became a Pathology Professor at Weill Cornell Medicine. Dr. Tang’s primary specialty is digestive diseases, particularly cancers of the GI tract and the pancreas. She holds a special interest in GI NETs and carcinoid disease. Her investigative research involves elucidating the molecular mechanisms of cell proliferation and the regulation of malignant cell transformation, with the goal of developing molecular techniques that will improve the early diagnosis and treatment of GI tract cancers. Dr. Tang is currently involved in a multidisciplinary investigation of Barrett’s-related dysplasia and esophageal cancer. She is also affiliated with Bellevue Hospital Center. Dr. Tang attended Capital University of Medicine and Sciences in Beijing, China. She later earned her doctoral degree in physiology from Emory University School of Medicine. She completed her fellowship at Yale University School of Medicine. She finished her GI Pathology Fellowship in 2003 at Memorial Sloan Kettering Cancer Center. She is board certified in anatomical pathology.
Tiffany Valone, PA-C, MS, OT

Physician Assistant & Supervisor, Division of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center & Research Institute

Tiffany has more than a decade of experience in the medical field working in a variety of roles: occupational therapist, orthopedic PA, best practice coordinator, supervisor of gastrointestinal advanced practice professionals, gastrointestinal oncology PA, and teaching/precepting PA students. She began working as a PA shortly after receiving her Master of Science in Physician Assistant Studies from Philadelphia University. She has spent the past 10 years working in gastrointestinal medical oncology at the H. Lee Moffitt Cancer Center & Research Institute. Her research and clinical interests are focused on neuroendocrine tumors and pancreatobiliary tumors. She has presented at state and national conferences. Furthermore, she is on the speaker’s bureau for Novartis, Taiho, Genentech, AbbVie, and Lexicon. Tiffany is a member of the Florida Society of Clinical Oncology, Association of Physician Assistants in Oncology, and North American Neuroendocrine Tumor Society. In 2015, Tiffany received the Advanced Practice Professional of the Year Award.

Yi-Zarn Wang, MD, DDS, FACS

Staff Surgeon, Physicians Medical Center

Dr. Wang earned his DDS degree at Kaohsiung Medical College in Kaohsiung, Taiwan, Republic of China. He earned his medical degree at the Oregon Health Sciences University School of Medicine. He completed his internship and residency in general surgery at Barnes Hospital/Washington University School of Medicine, where he worked along with renowned surgeons and received world-class surgical oncology discipline. Dr. Wang has held several teaching positions, including his most recent position as a Professor of Surgery at Louisiana State University Health Sciences Center School of Medicine. Currently, Dr. Wang is a Staff Surgeon at Physicians Medical Center. Dr. Wang’s clinical interests are in the treatment of NETs, hepatobiliary, pancreatic surgery, radiofrequency, and NanoKnife ablation of solid tumors. He has held positions as an expert panelist for AJCC Cancer Staging Manual 8th Edition and NANETS Guideline: Medical and Surgical Management of Small Bowel NETs. He is affiliated with several professional organizations, including American College of Surgeons, American Society of Colon and Rectal Surgeons, American Hepato-Pancreato-Biliary Association, Society of Surgical Oncology, American Association of Endocrine Surgeons, North American Neuroendocrine Tumor Society, and International Society of Gastrointestinal Oncology.
Donna Williams, RN, PHN
Senior Clinical Research Nurse, Stanford University School of Medicine
Donna has worked as a Senior Clinical Research Nurse at Stanford University since 2008. Prior to that, she worked as a Manager of Clinical Field Operations at CardioDX. Donna’s current interests are in clinical trial strategy and execution, immunotherapies, genetics, and gastrointestinal cancers. She is actively engaged in pioneering cancer care at Stanford. Donna holds a position on the Nurse Advisory Board for Lexicon Pharmaceuticals.

James Yao, MD
Professor & Department Chair, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Dr. Yao is a founding member and chair of the North American Neuroendocrine Tumor Society (NANETS). He is a Professor and Faculty Supervisor of the Mid-Level Providers Program, Executive Sponsor, and Department Chair in the Division of Cancer Medicine at MD Anderson Cancer Center. In addition, he serves as the chairman of the Ellen F. Knisely Distinguished Chair in Colon Cancer Research at MD Anderson Cancer Center. He earned his medical degree and completed his clinical residency at Baylor College of Medicine. He completed his clinical fellowship in 2001 at MD Anderson Cancer Center. Dr. Yao is an active member of the research community with a focus on examining therapeutic methods in NETs. He has served as a principal investigator on numerous phase 1, 2, and 3 clinical trials. Additionally, he has led many multicenter national and international clinical trials, including the phase 3 RADIANT-3 study that resulted in improving the standard of care for patients with advanced pancreatic NETs. He obtained a technology license for novel carcinoid cell line CNTD in 2006. In 2007, Dr. Yao disclosed a method of inhibiting angiogenesis by mithramycin, which is pending approval for patent. He is a member of numerous committees and a principal investigator of the Phase II Contract (N01) Committee. Dr. Yao serves on the National Cancer Institute (NCI) Investigational Drug Steering Committee, Investigational Drug Steering Committee Coordinating Team, and as Vice Chair of NCI Neuroendocrine Task Force. Furthermore, he has led the NCI Clinical Trial Planning Meeting for NETs. Dr. Yao is an active reviewer for the British Journal of Cancer; Clinical Cancer Research; Journal of Clinical Oncology; Oncology; European Journal of Cancer; Cancer Epidemiology, Biomarkers & Prevention; Endocrine-Related Cancer; New England Journal of Medicine; Science; and Cancer Research. He has chaired and given numerous invited lectures and presentations at national and international conferences, symposia, and meetings.
Dominic Yee, MD

*Endovascular Interventional Radiologist, RIA Endovascular*

Dr. Yee is an interventional radiologist at RIA Endovascular. His specialties include diagnostic radiology, vascular and interventional radiology, hepatobiliary, and liver transplant patients. His work focuses on a wide range of topics, such as thrombolytic therapy, dialysis access, kyphoplasty, cancer therapy, carotid stents, and transjugular intrahepatic portosystemic shunt (TIPS). He has completed more than 350 TIPS throughout his career. He is a member of Radiology Imaging Associates for more than 15 years and has over 10 years of experience as Section Chief for Interventional Radiology. He graduated from the University of Colorado Medical School and completed his diagnostic radiology residency at the University of Arizona Health Sciences Center. He completed his Interventional Radiology Fellowship at the University of Pennsylvania. Dr. Yee is affiliated with several hospitals, including Littleton Adventist Hospital, Medical Center of Aurora North, Porter Adventis Hospital, Sky Ridge Medical Center, Swedish Medical Center, The Medical Center of Aurora, and Aspen Valley Hospital District. He is a recipient of awards, including Physician of the Year in 2013. He has led 4 different research projects and has been a contributor to multiple publications and abstracts. He is an active member of the Society of Interventional Radiology and Colorado Radiological Society.

Mary Mitchell Zoeller, MSW

*Group Leader, Indiana Carcinoid Awareness Network (ICAN)*

Ms. Zoeller, a carcinoid patient, has been a part of the Indiana Carcinoid Awareness Network (ICAN) as a group leader since it began in 2008. As group leader, she plays an integral part in the communication and information hub. Prior to joining ICAN, she was a case investigator at a child welfare agency, and worked as a medical social worker. She focuses her efforts on understanding the presentations and manifestations of NETs. She is an advocate for diverse treatment plans in carcinoid and NETs. She is a member of the advisory board for ICAN Mary earned her BA and MSW degrees from Indiana University.